This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES: Oligonucleotide & Peptide Therapeutics Content Hub
24/7 Access
Digital & In-Person
Menu

Dieter Willbold, Ph.D.
Director, ICS-6 Structural Biochemistry at Forschungszentrum Jülich, Germany
Speaker

Profile

Dieter Willbold studied biochemistry in Tübingen (Germany), Bayreuth (Germany) and Boulder (Colorado, USA). He completed his PhD in 1994 at the University of Bayreuth. After some more years in Bayreuth and a couple of research visits, e.g. at the Sackler School of Medicine of the Tel-Aviv University, he was leading his junior research group at the Institute for Molecular Biotechnology in Jena, Germany. In 2001 Willbold became an associate Professor at the Heinrich Heine University in Düsseldorf. Since 2004, he is full professor at the Institute of Physical Biology in Düsseldorf and director of the Institute of Complex Systems at the Forschungszentrum Jülich. His main interests are protein interactions with physiological and artificial ligands, high resolution structural biology, neurodegeneration, neuropathic pain and autophagy.

Agenda Sessions

  • Five Pre-clinical PoC studies and the Clinical Phase I Study of the Orally Available All-D-enantiomeric Peptide PRI-002 for the Treatment of Alzheimer’s Disease

    On Demand - Premium Only
  • Five Pre-clinical PoC studies and the Clinical Phase I Study of the Orally Available All-D-enantiomeric Peptide PRI-002 for the Treatment of Alzheimer’s Disease

    On Demand - Premium Only